<DOC>
	<DOCNO>NCT02018627</DOCNO>
	<brief_summary>This study test hypothesis micro-doses Xerisol Glucagon ( Xeris Pharmaceuticals ) non-inferior pharmacokinetic pharmacodynamic criterion vs. micro-doses Glucagon Injection ( Eli Lilly ) .</brief_summary>
	<brief_title>Equivalence A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon</brief_title>
	<detailed_description>This study test hypothesis micro-doses new formulation stable glucagon , Xerisol Glucagon ( Xeris Pharmaceuticals ) , non-inferior pharmacokinetic pharmacodynamic criterion vs. micro-doses freshly reconstitute formulation glucagon poor stability solution , Glucagon Injection ( Eli Lilly ) .</detailed_description>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Age 21 80 year old type 1 diabetes least one year . Diabetes manage use insulin infusion pump use rapidacting insulin insulin aspart ( NovoLog ) , insulin lispro ( Humalog ) , insulin glulisine ( Apidra ) least one week prior enrollment . Unable provide inform consent . Unable comply study procedure . Current participation another diabetesrelated clinical trial , judgment principle investigator , compromise result clamp study safety subject . Pregnancy ( positive urine HCG ) , breast feeding , plan become pregnant immediate future , sexually active without use contraception . End stage renal disease dialysis ( hemodialysis peritoneal dialysis ) . Hemoglobin &lt; 11.5 gm/dl . History pheochromocytoma . Fractionated metanephrines test patient history increase risk catecholamine secrete tumor ( paroxysms tachycardia , pallor , headache ; personal family history MEN 2A , MEN 2B , neurofibromatosis , von HippelLindau disease ; episodic treatment refractory hypertension , define require 4 medication achieve normotension ) . History adverse reaction glucagon ( include allergy ) besides nausea , vomit , headache . Inadequate venous access determine study nurse physician time screen . Liver failure cirrhosis . Any factor , judgment principal investigator , would interfere safe completion study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>bionic pancreas</keyword>
	<keyword>artificial pancreas</keyword>
	<keyword>insulin</keyword>
	<keyword>glucagon</keyword>
	<keyword>clamp</keyword>
</DOC>